Silencing of STAMP1/STEAP2 and Amplification with Apoptosis Panel Primers

Authors

  • Ceren Gonen Ege University, Fac. of Pharmacy, Dept. of Pharmacology, Erzene Mahallesi Ankara Caddesi No:172/98, Bornova, Izmir, TURKEY, Post code: 35040

DOI:

https://doi.org/10.14738/bjhr.1205.19320

Keywords:

silencing of STAMP1/STEAP2, LNCaP, P53, RT-PCR, AR: Androgen receptor, ChIP: Chromatine Immunoprecipitation, RTqPCR: Quantitative polymerase chain reaction, TUBITAK: The Scientific and Technological Research Council of Turkey, STAMP: six transmembrane protein of prostate, TUBA: The Turkish Academy of Sciences

Abstract

Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer mortality in men in the Western World. The effects of androgens are mediated by the androgen receptor (AR). Therefore, studies focus on identification of AR regulated genes that are also highly expressed in the prostate. STAMP family genes STAMP1/STEAP2 (Korkmaz  KS., 2002) and STAMP2/STEAP4 (Korkmaz CG., 2005) are only expressed in androgen receptor positive cells, the role of AR in STAMP family gene expression is an important question. STEAP (six transmembrane epithelial antigen of prostate) (Hubert RS., 1999) is the first characterized prostate enriched six transmembrane gene, expressed in metastatic prostate cancer samples, it is tempting to speculate that STAMP/STEAP family genes may be involved in similar functions with a role for both the normal biology and pathophysiology of  prostate. Using siRNA technology in LNCaP cells expressing STAMP genes per se, an apoptosis panel including pro-apoptotic and/or apoptotic molecules was assayed by RT-PCR, By this research project, prostate-specific STAMP gene family and its regulatory effects were characterized.

Downloads

Published

2025-09-25

How to Cite

Gonen, C. (2025). Silencing of STAMP1/STEAP2 and Amplification with Apoptosis Panel Primers. British Journal of Healthcare and Medical Research, 12(05), 68–74. https://doi.org/10.14738/bjhr.1205.19320